nodes	percent_of_prediction	percent_of_DWPC	metapath
Rifaximin—CYP3A4—Vandetanib—thyroid cancer	0.0485	0.508	CbGbCtD
Rifaximin—CYP3A4—Sorafenib—thyroid cancer	0.0293	0.306	CbGbCtD
Rifaximin—CYP3A4—Doxorubicin—thyroid cancer	0.0178	0.186	CbGbCtD
Rifaximin—NR1I2—Nuclear Receptors—THRB—thyroid cancer	0.00332	0.216	CbGpPWpGaD
Rifaximin—Ageusia—Epirubicin—thyroid cancer	0.00318	0.00358	CcSEcCtD
Rifaximin—Fatigue—Vandetanib—thyroid cancer	0.00318	0.00358	CcSEcCtD
Rifaximin—Angiopathy—Sorafenib—thyroid cancer	0.00318	0.00358	CcSEcCtD
Rifaximin—Mediastinal disorder—Sorafenib—thyroid cancer	0.00316	0.00355	CcSEcCtD
Rifaximin—Pain—Vandetanib—thyroid cancer	0.00316	0.00355	CcSEcCtD
Rifaximin—Constipation—Vandetanib—thyroid cancer	0.00316	0.00355	CcSEcCtD
Rifaximin—Mental disorder—Sorafenib—thyroid cancer	0.00307	0.00345	CcSEcCtD
Rifaximin—Malnutrition—Sorafenib—thyroid cancer	0.00305	0.00343	CcSEcCtD
Rifaximin—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00302	0.0034	CcSEcCtD
Rifaximin—Ageusia—Doxorubicin—thyroid cancer	0.00295	0.00331	CcSEcCtD
Rifaximin—Muscle spasms—Sorafenib—thyroid cancer	0.00293	0.0033	CcSEcCtD
Rifaximin—Abdominal pain—Vandetanib—thyroid cancer	0.00292	0.00328	CcSEcCtD
Rifaximin—Body temperature increased—Vandetanib—thyroid cancer	0.00292	0.00328	CcSEcCtD
Rifaximin—Bone disorder—Epirubicin—thyroid cancer	0.00286	0.00321	CcSEcCtD
Rifaximin—Cellulitis—Epirubicin—thyroid cancer	0.00284	0.00319	CcSEcCtD
Rifaximin—Anaemia—Sorafenib—thyroid cancer	0.00282	0.00317	CcSEcCtD
Rifaximin—Angioedema—Sorafenib—thyroid cancer	0.00279	0.00314	CcSEcCtD
Rifaximin—Syncope—Sorafenib—thyroid cancer	0.00274	0.00308	CcSEcCtD
Rifaximin—Loss of consciousness—Sorafenib—thyroid cancer	0.00268	0.00302	CcSEcCtD
Rifaximin—Cough—Sorafenib—thyroid cancer	0.00266	0.00299	CcSEcCtD
Rifaximin—Asthenia—Vandetanib—thyroid cancer	0.00265	0.00298	CcSEcCtD
Rifaximin—Bone disorder—Doxorubicin—thyroid cancer	0.00264	0.00297	CcSEcCtD
Rifaximin—Cellulitis—Doxorubicin—thyroid cancer	0.00262	0.00295	CcSEcCtD
Rifaximin—NR1I2—Nuclear Receptor transcription pathway—THRB—thyroid cancer	0.00262	0.171	CbGpPWpGaD
Rifaximin—Pruritus—Vandetanib—thyroid cancer	0.00261	0.00294	CcSEcCtD
Rifaximin—Neck pain—Epirubicin—thyroid cancer	0.00261	0.00294	CcSEcCtD
Rifaximin—Arthralgia—Sorafenib—thyroid cancer	0.0026	0.00292	CcSEcCtD
Rifaximin—Myalgia—Sorafenib—thyroid cancer	0.0026	0.00292	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00258	0.0029	CcSEcCtD
Rifaximin—Abnormal dreams—Epirubicin—thyroid cancer	0.00255	0.00287	CcSEcCtD
Rifaximin—Dry mouth—Sorafenib—thyroid cancer	0.00254	0.00286	CcSEcCtD
Rifaximin—Hyperkalaemia—Epirubicin—thyroid cancer	0.00253	0.00285	CcSEcCtD
Rifaximin—Diarrhoea—Vandetanib—thyroid cancer	0.00253	0.00284	CcSEcCtD
Rifaximin—Influenza like illness—Epirubicin—thyroid cancer	0.00251	0.00282	CcSEcCtD
Rifaximin—Anaphylactic shock—Sorafenib—thyroid cancer	0.00249	0.0028	CcSEcCtD
Rifaximin—Colitis—Epirubicin—thyroid cancer	0.00248	0.00279	CcSEcCtD
Rifaximin—Infection—Sorafenib—thyroid cancer	0.00247	0.00278	CcSEcCtD
Rifaximin—Shock—Sorafenib—thyroid cancer	0.00245	0.00276	CcSEcCtD
Rifaximin—Fluid retention—Epirubicin—thyroid cancer	0.00245	0.00275	CcSEcCtD
Rifaximin—Nervous system disorder—Sorafenib—thyroid cancer	0.00244	0.00275	CcSEcCtD
Rifaximin—Dizziness—Vandetanib—thyroid cancer	0.00244	0.00275	CcSEcCtD
Rifaximin—Skin disorder—Sorafenib—thyroid cancer	0.00242	0.00272	CcSEcCtD
Rifaximin—Neck pain—Doxorubicin—thyroid cancer	0.00242	0.00272	CcSEcCtD
Rifaximin—Anorexia—Sorafenib—thyroid cancer	0.00237	0.00267	CcSEcCtD
Rifaximin—Abnormal dreams—Doxorubicin—thyroid cancer	0.00236	0.00265	CcSEcCtD
Rifaximin—Vomiting—Vandetanib—thyroid cancer	0.00235	0.00264	CcSEcCtD
Rifaximin—Hyperkalaemia—Doxorubicin—thyroid cancer	0.00235	0.00264	CcSEcCtD
Rifaximin—Rash—Vandetanib—thyroid cancer	0.00233	0.00262	CcSEcCtD
Rifaximin—Dermatitis—Vandetanib—thyroid cancer	0.00233	0.00262	CcSEcCtD
Rifaximin—Influenza like illness—Doxorubicin—thyroid cancer	0.00232	0.00261	CcSEcCtD
Rifaximin—Headache—Vandetanib—thyroid cancer	0.00231	0.0026	CcSEcCtD
Rifaximin—Colitis—Doxorubicin—thyroid cancer	0.00229	0.00258	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00227	0.00255	CcSEcCtD
Rifaximin—Fluid retention—Doxorubicin—thyroid cancer	0.00227	0.00255	CcSEcCtD
Rifaximin—Dyspnoea—Sorafenib—thyroid cancer	0.00222	0.0025	CcSEcCtD
Rifaximin—Nausea—Vandetanib—thyroid cancer	0.00219	0.00247	CcSEcCtD
Rifaximin—Decreased appetite—Sorafenib—thyroid cancer	0.00216	0.00243	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00215	0.00242	CcSEcCtD
Rifaximin—Fatigue—Sorafenib—thyroid cancer	0.00215	0.00241	CcSEcCtD
Rifaximin—Pain—Sorafenib—thyroid cancer	0.00213	0.0024	CcSEcCtD
Rifaximin—Constipation—Sorafenib—thyroid cancer	0.00213	0.0024	CcSEcCtD
Rifaximin—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00204	0.00229	CcSEcCtD
Rifaximin—Hot flush—Epirubicin—thyroid cancer	0.002	0.00225	CcSEcCtD
Rifaximin—Dermatitis exfoliative—Epirubicin—thyroid cancer	0.00198	0.00223	CcSEcCtD
Rifaximin—Menopausal symptoms—Epirubicin—thyroid cancer	0.00198	0.00223	CcSEcCtD
Rifaximin—Urticaria—Sorafenib—thyroid cancer	0.00198	0.00223	CcSEcCtD
Rifaximin—Abdominal pain—Sorafenib—thyroid cancer	0.00197	0.00221	CcSEcCtD
Rifaximin—Body temperature increased—Sorafenib—thyroid cancer	0.00197	0.00221	CcSEcCtD
Rifaximin—Hypoglycaemia—Epirubicin—thyroid cancer	0.00192	0.00216	CcSEcCtD
Rifaximin—Hyponatraemia—Epirubicin—thyroid cancer	0.00188	0.00211	CcSEcCtD
Rifaximin—Pain in extremity—Epirubicin—thyroid cancer	0.00187	0.00211	CcSEcCtD
Rifaximin—Hot flush—Doxorubicin—thyroid cancer	0.00185	0.00208	CcSEcCtD
Rifaximin—Migraine—Epirubicin—thyroid cancer	0.00184	0.00207	CcSEcCtD
Rifaximin—Dermatitis exfoliative—Doxorubicin—thyroid cancer	0.00184	0.00207	CcSEcCtD
Rifaximin—Menopausal symptoms—Doxorubicin—thyroid cancer	0.00184	0.00207	CcSEcCtD
Rifaximin—Hypersensitivity—Sorafenib—thyroid cancer	0.00183	0.00206	CcSEcCtD
Rifaximin—Asthenia—Sorafenib—thyroid cancer	0.00179	0.00201	CcSEcCtD
Rifaximin—Hypoglycaemia—Doxorubicin—thyroid cancer	0.00178	0.002	CcSEcCtD
Rifaximin—Pruritus—Sorafenib—thyroid cancer	0.00176	0.00198	CcSEcCtD
Rifaximin—Dehydration—Epirubicin—thyroid cancer	0.00174	0.00196	CcSEcCtD
Rifaximin—Hyponatraemia—Doxorubicin—thyroid cancer	0.00174	0.00196	CcSEcCtD
Rifaximin—Pain in extremity—Doxorubicin—thyroid cancer	0.00173	0.00195	CcSEcCtD
Rifaximin—Abdominal pain upper—Epirubicin—thyroid cancer	0.00171	0.00192	CcSEcCtD
Rifaximin—Migraine—Doxorubicin—thyroid cancer	0.00171	0.00192	CcSEcCtD
Rifaximin—Diarrhoea—Sorafenib—thyroid cancer	0.0017	0.00192	CcSEcCtD
Rifaximin—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.00169	0.0019	CcSEcCtD
Rifaximin—Nasopharyngitis—Epirubicin—thyroid cancer	0.00167	0.00188	CcSEcCtD
Rifaximin—Dizziness—Sorafenib—thyroid cancer	0.00165	0.00185	CcSEcCtD
Rifaximin—Abdominal distension—Epirubicin—thyroid cancer	0.00163	0.00183	CcSEcCtD
Rifaximin—Dysphagia—Epirubicin—thyroid cancer	0.00162	0.00182	CcSEcCtD
Rifaximin—Dehydration—Doxorubicin—thyroid cancer	0.00161	0.00181	CcSEcCtD
Rifaximin—Vomiting—Sorafenib—thyroid cancer	0.00158	0.00178	CcSEcCtD
Rifaximin—Abdominal pain upper—Doxorubicin—thyroid cancer	0.00158	0.00178	CcSEcCtD
Rifaximin—Rash—Sorafenib—thyroid cancer	0.00157	0.00177	CcSEcCtD
Rifaximin—Dermatitis—Sorafenib—thyroid cancer	0.00157	0.00176	CcSEcCtD
Rifaximin—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.00156	0.00175	CcSEcCtD
Rifaximin—Headache—Sorafenib—thyroid cancer	0.00156	0.00175	CcSEcCtD
Rifaximin—Nasopharyngitis—Doxorubicin—thyroid cancer	0.00155	0.00174	CcSEcCtD
Rifaximin—Dysuria—Epirubicin—thyroid cancer	0.00151	0.0017	CcSEcCtD
Rifaximin—Neutropenia—Epirubicin—thyroid cancer	0.00151	0.0017	CcSEcCtD
Rifaximin—Abdominal distension—Doxorubicin—thyroid cancer	0.00151	0.0017	CcSEcCtD
Rifaximin—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.0015	0.00169	CcSEcCtD
Rifaximin—Dysphagia—Doxorubicin—thyroid cancer	0.0015	0.00168	CcSEcCtD
Rifaximin—Pollakiuria—Epirubicin—thyroid cancer	0.0015	0.00168	CcSEcCtD
Rifaximin—Nausea—Sorafenib—thyroid cancer	0.00148	0.00166	CcSEcCtD
Rifaximin—Photosensitivity reaction—Epirubicin—thyroid cancer	0.00148	0.00166	CcSEcCtD
Rifaximin—Weight increased—Epirubicin—thyroid cancer	0.00147	0.00166	CcSEcCtD
Rifaximin—Weight decreased—Epirubicin—thyroid cancer	0.00146	0.00165	CcSEcCtD
Rifaximin—Hyperglycaemia—Epirubicin—thyroid cancer	0.00146	0.00164	CcSEcCtD
Rifaximin—Pneumonia—Epirubicin—thyroid cancer	0.00145	0.00163	CcSEcCtD
Rifaximin—Infestation NOS—Epirubicin—thyroid cancer	0.00144	0.00162	CcSEcCtD
Rifaximin—Infestation—Epirubicin—thyroid cancer	0.00144	0.00162	CcSEcCtD
Rifaximin—NR1I2—Nuclear Receptors—RXRA—thyroid cancer	0.00141	0.0919	CbGpPWpGaD
Rifaximin—Dysuria—Doxorubicin—thyroid cancer	0.0014	0.00158	CcSEcCtD
Rifaximin—Neutropenia—Doxorubicin—thyroid cancer	0.0014	0.00158	CcSEcCtD
Rifaximin—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.00139	0.00157	CcSEcCtD
Rifaximin—Pollakiuria—Doxorubicin—thyroid cancer	0.00138	0.00156	CcSEcCtD
Rifaximin—Haematuria—Epirubicin—thyroid cancer	0.00138	0.00155	CcSEcCtD
Rifaximin—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.00137	0.00154	CcSEcCtD
Rifaximin—Weight increased—Doxorubicin—thyroid cancer	0.00136	0.00153	CcSEcCtD
Rifaximin—Epistaxis—Epirubicin—thyroid cancer	0.00136	0.00153	CcSEcCtD
Rifaximin—Weight decreased—Doxorubicin—thyroid cancer	0.00135	0.00152	CcSEcCtD
Rifaximin—Hyperglycaemia—Doxorubicin—thyroid cancer	0.00135	0.00152	CcSEcCtD
Rifaximin—Pneumonia—Doxorubicin—thyroid cancer	0.00134	0.00151	CcSEcCtD
Rifaximin—Infestation NOS—Doxorubicin—thyroid cancer	0.00134	0.0015	CcSEcCtD
Rifaximin—Infestation—Doxorubicin—thyroid cancer	0.00134	0.0015	CcSEcCtD
Rifaximin—Haemoglobin—Epirubicin—thyroid cancer	0.0013	0.00146	CcSEcCtD
Rifaximin—Rhinitis—Epirubicin—thyroid cancer	0.0013	0.00146	CcSEcCtD
Rifaximin—Haemorrhage—Epirubicin—thyroid cancer	0.0013	0.00146	CcSEcCtD
Rifaximin—Hypoaesthesia—Epirubicin—thyroid cancer	0.00129	0.00145	CcSEcCtD
Rifaximin—Pharyngitis—Epirubicin—thyroid cancer	0.00129	0.00145	CcSEcCtD
Rifaximin—Urinary tract disorder—Epirubicin—thyroid cancer	0.00128	0.00144	CcSEcCtD
Rifaximin—Oedema peripheral—Epirubicin—thyroid cancer	0.00128	0.00144	CcSEcCtD
Rifaximin—Haematuria—Doxorubicin—thyroid cancer	0.00127	0.00143	CcSEcCtD
Rifaximin—Urethral disorder—Epirubicin—thyroid cancer	0.00127	0.00143	CcSEcCtD
Rifaximin—Epistaxis—Doxorubicin—thyroid cancer	0.00126	0.00142	CcSEcCtD
Rifaximin—Tinnitus—Epirubicin—thyroid cancer	0.00121	0.00136	CcSEcCtD
Rifaximin—Haemoglobin—Doxorubicin—thyroid cancer	0.0012	0.00136	CcSEcCtD
Rifaximin—Flushing—Epirubicin—thyroid cancer	0.0012	0.00135	CcSEcCtD
Rifaximin—Rhinitis—Doxorubicin—thyroid cancer	0.0012	0.00135	CcSEcCtD
Rifaximin—Haemorrhage—Doxorubicin—thyroid cancer	0.0012	0.00135	CcSEcCtD
Rifaximin—Hypoaesthesia—Doxorubicin—thyroid cancer	0.00119	0.00134	CcSEcCtD
Rifaximin—Pharyngitis—Doxorubicin—thyroid cancer	0.00119	0.00134	CcSEcCtD
Rifaximin—Urinary tract disorder—Doxorubicin—thyroid cancer	0.00118	0.00133	CcSEcCtD
Rifaximin—Oedema peripheral—Doxorubicin—thyroid cancer	0.00118	0.00133	CcSEcCtD
Rifaximin—Angiopathy—Epirubicin—thyroid cancer	0.00118	0.00132	CcSEcCtD
Rifaximin—Urethral disorder—Doxorubicin—thyroid cancer	0.00117	0.00132	CcSEcCtD
Rifaximin—Mediastinal disorder—Epirubicin—thyroid cancer	0.00117	0.00131	CcSEcCtD
Rifaximin—Mental disorder—Epirubicin—thyroid cancer	0.00113	0.00128	CcSEcCtD
Rifaximin—Malnutrition—Epirubicin—thyroid cancer	0.00113	0.00127	CcSEcCtD
Rifaximin—Tinnitus—Doxorubicin—thyroid cancer	0.00112	0.00126	CcSEcCtD
Rifaximin—NR1I2—Nuclear Receptor transcription pathway—RXRA—thyroid cancer	0.00111	0.0726	CbGpPWpGaD
Rifaximin—Flushing—Doxorubicin—thyroid cancer	0.00111	0.00125	CcSEcCtD
Rifaximin—Flatulence—Epirubicin—thyroid cancer	0.00111	0.00125	CcSEcCtD
Rifaximin—Back pain—Epirubicin—thyroid cancer	0.00109	0.00123	CcSEcCtD
Rifaximin—Angiopathy—Doxorubicin—thyroid cancer	0.00109	0.00122	CcSEcCtD
Rifaximin—Muscle spasms—Epirubicin—thyroid cancer	0.00108	0.00122	CcSEcCtD
Rifaximin—Mediastinal disorder—Doxorubicin—thyroid cancer	0.00108	0.00122	CcSEcCtD
Rifaximin—Mental disorder—Doxorubicin—thyroid cancer	0.00105	0.00118	CcSEcCtD
Rifaximin—Ill-defined disorder—Epirubicin—thyroid cancer	0.00105	0.00118	CcSEcCtD
Rifaximin—Malnutrition—Doxorubicin—thyroid cancer	0.00104	0.00117	CcSEcCtD
Rifaximin—Anaemia—Epirubicin—thyroid cancer	0.00104	0.00117	CcSEcCtD
Rifaximin—Flatulence—Doxorubicin—thyroid cancer	0.00103	0.00116	CcSEcCtD
Rifaximin—Malaise—Epirubicin—thyroid cancer	0.00102	0.00114	CcSEcCtD
Rifaximin—Vertigo—Epirubicin—thyroid cancer	0.00101	0.00114	CcSEcCtD
Rifaximin—Syncope—Epirubicin—thyroid cancer	0.00101	0.00114	CcSEcCtD
Rifaximin—Back pain—Doxorubicin—thyroid cancer	0.00101	0.00114	CcSEcCtD
Rifaximin—Muscle spasms—Doxorubicin—thyroid cancer	0.001	0.00113	CcSEcCtD
Rifaximin—Loss of consciousness—Epirubicin—thyroid cancer	0.000991	0.00111	CcSEcCtD
Rifaximin—Cough—Epirubicin—thyroid cancer	0.000984	0.00111	CcSEcCtD
Rifaximin—NR1I2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000973	0.0634	CbGpPWpGaD
Rifaximin—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000968	0.00109	CcSEcCtD
Rifaximin—Anaemia—Doxorubicin—thyroid cancer	0.000964	0.00108	CcSEcCtD
Rifaximin—Arthralgia—Epirubicin—thyroid cancer	0.00096	0.00108	CcSEcCtD
Rifaximin—Myalgia—Epirubicin—thyroid cancer	0.00096	0.00108	CcSEcCtD
Rifaximin—Chest pain—Epirubicin—thyroid cancer	0.00096	0.00108	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000953	0.00107	CcSEcCtD
Rifaximin—Discomfort—Epirubicin—thyroid cancer	0.000949	0.00107	CcSEcCtD
Rifaximin—Malaise—Doxorubicin—thyroid cancer	0.000941	0.00106	CcSEcCtD
Rifaximin—Dry mouth—Epirubicin—thyroid cancer	0.000939	0.00106	CcSEcCtD
Rifaximin—Vertigo—Doxorubicin—thyroid cancer	0.000937	0.00105	CcSEcCtD
Rifaximin—Syncope—Doxorubicin—thyroid cancer	0.000936	0.00105	CcSEcCtD
Rifaximin—Confusional state—Epirubicin—thyroid cancer	0.000928	0.00104	CcSEcCtD
Rifaximin—Anaphylactic shock—Epirubicin—thyroid cancer	0.00092	0.00104	CcSEcCtD
Rifaximin—Loss of consciousness—Doxorubicin—thyroid cancer	0.000917	0.00103	CcSEcCtD
Rifaximin—Infection—Epirubicin—thyroid cancer	0.000914	0.00103	CcSEcCtD
Rifaximin—Cough—Doxorubicin—thyroid cancer	0.000911	0.00102	CcSEcCtD
Rifaximin—Shock—Epirubicin—thyroid cancer	0.000905	0.00102	CcSEcCtD
Rifaximin—Nervous system disorder—Epirubicin—thyroid cancer	0.000903	0.00102	CcSEcCtD
Rifaximin—Skin disorder—Epirubicin—thyroid cancer	0.000894	0.00101	CcSEcCtD
Rifaximin—NR1I2—Nuclear Receptors—PPARG—thyroid cancer	0.00089	0.058	CbGpPWpGaD
Rifaximin—Hyperhidrosis—Epirubicin—thyroid cancer	0.00089	0.001	CcSEcCtD
Rifaximin—Myalgia—Doxorubicin—thyroid cancer	0.000888	0.000999	CcSEcCtD
Rifaximin—Chest pain—Doxorubicin—thyroid cancer	0.000888	0.000999	CcSEcCtD
Rifaximin—Arthralgia—Doxorubicin—thyroid cancer	0.000888	0.000999	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000882	0.000992	CcSEcCtD
Rifaximin—Discomfort—Doxorubicin—thyroid cancer	0.000878	0.000987	CcSEcCtD
Rifaximin—Anorexia—Epirubicin—thyroid cancer	0.000877	0.000987	CcSEcCtD
Rifaximin—Dry mouth—Doxorubicin—thyroid cancer	0.000869	0.000977	CcSEcCtD
Rifaximin—Hypotension—Epirubicin—thyroid cancer	0.00086	0.000967	CcSEcCtD
Rifaximin—Confusional state—Doxorubicin—thyroid cancer	0.000859	0.000966	CcSEcCtD
Rifaximin—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000852	0.000958	CcSEcCtD
Rifaximin—Infection—Doxorubicin—thyroid cancer	0.000846	0.000952	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000839	0.000943	CcSEcCtD
Rifaximin—Shock—Doxorubicin—thyroid cancer	0.000838	0.000942	CcSEcCtD
Rifaximin—Nervous system disorder—Doxorubicin—thyroid cancer	0.000835	0.000939	CcSEcCtD
Rifaximin—Insomnia—Epirubicin—thyroid cancer	0.000832	0.000936	CcSEcCtD
Rifaximin—Skin disorder—Doxorubicin—thyroid cancer	0.000827	0.00093	CcSEcCtD
Rifaximin—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000823	0.000926	CcSEcCtD
Rifaximin—Dyspnoea—Epirubicin—thyroid cancer	0.000821	0.000923	CcSEcCtD
Rifaximin—Anorexia—Doxorubicin—thyroid cancer	0.000812	0.000913	CcSEcCtD
Rifaximin—Decreased appetite—Epirubicin—thyroid cancer	0.0008	0.0009	CcSEcCtD
Rifaximin—Hypotension—Doxorubicin—thyroid cancer	0.000796	0.000895	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000795	0.000894	CcSEcCtD
Rifaximin—Fatigue—Epirubicin—thyroid cancer	0.000793	0.000892	CcSEcCtD
Rifaximin—Pain—Epirubicin—thyroid cancer	0.000787	0.000885	CcSEcCtD
Rifaximin—Constipation—Epirubicin—thyroid cancer	0.000787	0.000885	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000776	0.000873	CcSEcCtD
Rifaximin—Insomnia—Doxorubicin—thyroid cancer	0.00077	0.000866	CcSEcCtD
Rifaximin—Dyspnoea—Doxorubicin—thyroid cancer	0.000759	0.000854	CcSEcCtD
Rifaximin—Feeling abnormal—Epirubicin—thyroid cancer	0.000758	0.000853	CcSEcCtD
Rifaximin—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000753	0.000846	CcSEcCtD
Rifaximin—Decreased appetite—Doxorubicin—thyroid cancer	0.00074	0.000833	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000735	0.000827	CcSEcCtD
Rifaximin—Fatigue—Doxorubicin—thyroid cancer	0.000734	0.000826	CcSEcCtD
Rifaximin—Urticaria—Epirubicin—thyroid cancer	0.000731	0.000822	CcSEcCtD
Rifaximin—Pain—Doxorubicin—thyroid cancer	0.000728	0.000819	CcSEcCtD
Rifaximin—Constipation—Doxorubicin—thyroid cancer	0.000728	0.000819	CcSEcCtD
Rifaximin—Abdominal pain—Epirubicin—thyroid cancer	0.000728	0.000818	CcSEcCtD
Rifaximin—Body temperature increased—Epirubicin—thyroid cancer	0.000728	0.000818	CcSEcCtD
Rifaximin—NR1I2—Nuclear Receptor transcription pathway—PPARG—thyroid cancer	0.000704	0.0458	CbGpPWpGaD
Rifaximin—Feeling abnormal—Doxorubicin—thyroid cancer	0.000702	0.000789	CcSEcCtD
Rifaximin—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000696	0.000783	CcSEcCtD
Rifaximin—Hypersensitivity—Epirubicin—thyroid cancer	0.000678	0.000763	CcSEcCtD
Rifaximin—Urticaria—Doxorubicin—thyroid cancer	0.000677	0.000761	CcSEcCtD
Rifaximin—Body temperature increased—Doxorubicin—thyroid cancer	0.000673	0.000757	CcSEcCtD
Rifaximin—Abdominal pain—Doxorubicin—thyroid cancer	0.000673	0.000757	CcSEcCtD
Rifaximin—Asthenia—Epirubicin—thyroid cancer	0.00066	0.000743	CcSEcCtD
Rifaximin—Pruritus—Epirubicin—thyroid cancer	0.000651	0.000732	CcSEcCtD
Rifaximin—Diarrhoea—Epirubicin—thyroid cancer	0.00063	0.000708	CcSEcCtD
Rifaximin—Hypersensitivity—Doxorubicin—thyroid cancer	0.000627	0.000706	CcSEcCtD
Rifaximin—NR1I2—Generic Transcription Pathway—TRIM33—thyroid cancer	0.000627	0.0408	CbGpPWpGaD
Rifaximin—Asthenia—Doxorubicin—thyroid cancer	0.000611	0.000687	CcSEcCtD
Rifaximin—Dizziness—Epirubicin—thyroid cancer	0.000609	0.000685	CcSEcCtD
Rifaximin—Pruritus—Doxorubicin—thyroid cancer	0.000602	0.000678	CcSEcCtD
Rifaximin—Vomiting—Epirubicin—thyroid cancer	0.000585	0.000658	CcSEcCtD
Rifaximin—Diarrhoea—Doxorubicin—thyroid cancer	0.000583	0.000655	CcSEcCtD
Rifaximin—Rash—Epirubicin—thyroid cancer	0.00058	0.000653	CcSEcCtD
Rifaximin—Dermatitis—Epirubicin—thyroid cancer	0.00058	0.000652	CcSEcCtD
Rifaximin—Headache—Epirubicin—thyroid cancer	0.000577	0.000649	CcSEcCtD
Rifaximin—Dizziness—Doxorubicin—thyroid cancer	0.000563	0.000633	CcSEcCtD
Rifaximin—Nausea—Epirubicin—thyroid cancer	0.000547	0.000615	CcSEcCtD
Rifaximin—Vomiting—Doxorubicin—thyroid cancer	0.000541	0.000609	CcSEcCtD
Rifaximin—Rash—Doxorubicin—thyroid cancer	0.000537	0.000604	CcSEcCtD
Rifaximin—Dermatitis—Doxorubicin—thyroid cancer	0.000536	0.000603	CcSEcCtD
Rifaximin—Headache—Doxorubicin—thyroid cancer	0.000533	0.0006	CcSEcCtD
Rifaximin—Nausea—Doxorubicin—thyroid cancer	0.000506	0.000569	CcSEcCtD
Rifaximin—CYP3A4—Liver X Receptor Pathway—RXRA—thyroid cancer	0.000475	0.0309	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—THRB—thyroid cancer	0.000453	0.0295	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—TRIM33—thyroid cancer	0.000302	0.0197	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—MEN1—thyroid cancer	0.000288	0.0187	CbGpPWpGaD
Rifaximin—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.000284	0.0185	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—THRB—thyroid cancer	0.000218	0.0142	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—RXRA—thyroid cancer	0.000193	0.0125	CbGpPWpGaD
Rifaximin—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000187	0.0122	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.000165	0.0108	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—TPR—thyroid cancer	0.000147	0.0096	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—MEN1—thyroid cancer	0.000139	0.00903	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—PPARG—thyroid cancer	0.000122	0.00792	CbGpPWpGaD
Rifaximin—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000113	0.00737	CbGpPWpGaD
Rifaximin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000113	0.00733	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—RXRA—thyroid cancer	9.27e-05	0.00604	CbGpPWpGaD
Rifaximin—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	9.18e-05	0.00598	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—PPARG—thyroid cancer	5.85e-05	0.00381	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—RXRA—thyroid cancer	4.87e-05	0.00318	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—MINPP1—thyroid cancer	3.58e-05	0.00233	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—NDUFA13—thyroid cancer	3.04e-05	0.00198	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CHST14—thyroid cancer	2.86e-05	0.00186	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—AKT1—thyroid cancer	2.31e-05	0.00151	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—HPGD—thyroid cancer	2.31e-05	0.0015	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—TPR—thyroid cancer	1.33e-05	0.000863	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	1.3e-05	0.000849	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—SLC5A5—thyroid cancer	9.92e-06	0.000646	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—RXRA—thyroid cancer	8.34e-06	0.000543	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PPARG—thyroid cancer	5.26e-06	0.000343	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PTGS2—thyroid cancer	4.14e-06	0.00027	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PTEN—thyroid cancer	3.61e-06	0.000235	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—AKT1—thyroid cancer	2.08e-06	0.000136	CbGpPWpGaD
